{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:02:12Z","timestamp":1790240532406,"version":"4.1.0"},"reference-count":75,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoantibodies toward clotting factors may develop in people suffering from autoimmune or neoplastic diseases, after drug intake or even in subjects without apparent conditions. They are more commonly directed against factor VIII (FVIII) or von Willebrand factor leading to acquired hemophilia A or acquired von Willebrand syndrome, respectively. Rarely, autoantibodies develop against other clotting factors, such as fibrinogen, FII, FV, FVII, FX, FXI, and FXIII. The clinical picture of an acquired bleeding disorder includes a wide spectrum of clinical manifestations ranging from minimal or no bleeding to life-threatening events. Patients with no previous personal or family history of bleeding may have sudden-onset hemorrhagic manifestations, sometimes fatal, especially if an early diagnosis is not made. On the other hand, some patients may not have hemorrhagic symptoms at onset, and their diagnosis can therefore be delayed. The laboratory diagnostic assessment is performed by screening coagulation tests followed by specific factor-level measurement and inhibitor-titrating assays. An early diagnosis of acquired coagulopathies is mandatory for starting the appropriate treatment aimed at both controlling the acute bleeding episode mainly using the bypassing agents, and eradicating the anticlotting factor autoantibody, using immunosuppressive treatment. Therefore, prompt intervention by an expert and a specialized center is needed for immediate recognition and treatment of the disease.<\/jats:p>","DOI":"10.1182\/hematology.2019000066","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:16:48Z","timestamp":1575645408000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Management of rare acquired bleeding disorders"],"prefix":"10.1182","volume":"2019","author":[{"given":"Marzia","family":"Menegatti","sequence":"first","affiliation":[{"name":"Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Biguzzi","sequence":"additional","affiliation":[{"name":"Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; and"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019120610113563000_B1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM199203193261205","article-title":"Molecular and cellular biology of blood coagulation","volume":"326","author":"Furie","year":"1992","journal-title":"N Engl J Med"},{"issue":"13","key":"2019120610113563000_B2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment","volume":"125","author":"Palla","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019120610113563000_B3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF02737641","article-title":"Autoantibodies to coagulation factors and bleeding disorders","volume":"16","author":"Ahmed","year":"1998","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2019120610113563000_B4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.13424","article-title":"Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review","volume":"24","author":"Miller","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"2019120610113563000_B5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019120610113563000_B6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","article-title":"Acquired hemophilia A: a review of recent data and new therapeutic options","volume":"22","author":"Franchini","year":"2017","journal-title":"Hematology"},{"issue":"3","key":"2019120610113563000_B7","first-page":"498","article-title":"Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management","volume":"13","author":"Franchini","year":"2015","journal-title":"Blood Transfus"},{"issue":"4","key":"2019120610113563000_B8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.pop.2016.07.009","article-title":"Bleeding diatheses: approach to the patient who bleeds or has abnormal coagulation","volume":"43","author":"Paddock","year":"2016","journal-title":"Prim Care"},{"issue":"2","key":"2019120610113563000_B9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/rth2.12028","article-title":"Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases","volume":"1","author":"Lisman","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"2019120610113563000_B10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/17474086.2018.1500173","article-title":"Disseminated intravascular coagulation: an update on pathogenesis and diagnosis","volume":"11","author":"Levi","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2019120610113563000_B11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0049-3848(01)00385-1","article-title":"Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease","volume":"104","author":"Matsumoto","year":"2001","journal-title":"Thromb Res"},{"issue":"6","key":"2019120610113563000_B12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.transci.2018.10.012","article-title":"Management of acquired von Willebrand syndrome","volume":"57","author":"Charlebois","year":"2018","journal-title":"Transfus Apheresis Sci"},{"issue":"5","key":"2019120610113563000_B13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1055\/s-0032-1305779","article-title":"Acquired inhibitors of coagulation factors: part II","volume":"38","author":"Franchini","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"2019120610113563000_B14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1756-0500-3-161","article-title":"Consensus recommendations for the diagnosis and treatment of acquired hemophilia A","volume":"3","author":"Collins","year":"2010","journal-title":"BMC Res Notes"},{"issue":"5","key":"2019120610113563000_B15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0032-1315757","article-title":"Acquired inhibitors of coagulation factors: part I-acquired hemophilia A","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2019120610113563000_B16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.autrev.2013.08.001","article-title":"Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy [published correction appears in Autoimmun Rev. 2015;14(7):650]","volume":"13","author":"Cugno","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"4","key":"2019120610113563000_B17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pbc.22657","article-title":"Acquired hemophilia in pediatrics: a systematic review","volume":"55","author":"Franchini","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2019120610113563000_B18","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019120610113563000_B19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG"},{"issue":"suppl 3","key":"2019120610113563000_B20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2516.2008.01745.x","article-title":"Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome","volume":"14","author":"Collins","year":"2008","journal-title":"Haemophilia"},{"issue":"2","key":"2019120610113563000_B21","first-page":"345","article-title":"Acquired von Willebrand syndrome: data from an international registry [published correction appears in Thromb Haemost. 2000;84(4):739]","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019120610113563000_B22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","article-title":"Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study","volume":"6","author":"Tiede","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019120610113563000_B23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11239-010-0529-6","article-title":"Acquired factor V inhibitors: a systematic review","volume":"31","author":"Franchini","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2019120610113563000_B24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0030-1255441","article-title":"Topical recombinant human thrombin in surgical hemostasis","volume":"36","author":"Bowman","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2019120610113563000_B25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1055\/s-0037-1615103","article-title":"Antibodies against fibrinogen in pregnant women, in post delivery women and in the newborns","volume":"79","author":"Kondera-Anasz","year":"1998","journal-title":"Thromb Haemost"},{"issue":"11","key":"2019120610113563000_B26","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.3324\/haematol.11837","article-title":"Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain","volume":"92","author":"Dear","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"2019120610113563000_B27","first-page":"696","article-title":"Acquired dysfibrinogenemia caused by autoantibody inhibiting fibrin polymerization in a patient with MELAS syndrome and bleeding tendency","volume":"46","author":"Lee","year":"2016","journal-title":"Ann Clin Lab Sci"},{"issue":"3","key":"2019120610113563000_B28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2141.1993.tb03343.x","article-title":"Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V","volume":"85","author":"B\u00e4nninger","year":"1993","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120610113563000_B29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00000658-200101000-00014","article-title":"Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin","volume":"233","author":"Ortel","year":"2001","journal-title":"Ann Surg"},{"issue":"11","key":"2019120610113563000_B30","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.amjmed.2015.06.011","article-title":"Bruised black and blue: acquired hypoprothrombinemia","volume":"128","author":"Huang","year":"2015","journal-title":"Am J Med"},{"issue":"2","key":"2019120610113563000_B31","first-page":"63","article-title":"Isolated acquired factor VII deficiency: review of the literature","volume":"71","author":"Mulliez","year":"2016","journal-title":"Acta Clin Belg"},{"issue":"1","key":"2019120610113563000_B32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1613758","article-title":"Purification and characterization of factor VII inhibitor found in a patient with life threatening bleeding","volume":"83","author":"Kamikubo","year":"2000","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019120610113563000_B33","first-page":"132","article-title":"Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone","volume":"5","author":"Mazzucconi","year":"1999","journal-title":"Haemophilia"},{"issue":"4","key":"2019120610113563000_B34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2516.2010.02457.x","article-title":"A rare case of an acquired inhibitor to factor IX","volume":"17","author":"Krishnamurthy","year":"2011","journal-title":"Haemophilia"},{"issue":"7","key":"2019120610113563000_B35","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/j.amjmed.2017.01.046","article-title":"An acquired factor X inhibitor: the importance of understanding coagulation","volume":"130","author":"Chan","year":"2017","journal-title":"Am J Med"},{"issue":"1","key":"2019120610113563000_B36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.hemonc.2018.05.002","article-title":"Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease","volume":"12","author":"Patel","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"2019120610113563000_B37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197707142970203","article-title":"Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X","volume":"297","author":"Furie","year":"1977","journal-title":"N Engl J Med"},{"issue":"3","key":"2019120610113563000_B38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archinte.1983.00350030211041","article-title":"Resolution of factor X deficiency in primary amyloidosis following splenectomy","volume":"143","author":"Rosenstein","year":"1983","journal-title":"Arch Intern Med"},{"issue":"4","key":"2019120610113563000_B39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ajh.2830110414","article-title":"Factor-X deficiency in amyloidosis: a critical review","volume":"11","author":"Greipp","year":"1981","journal-title":"Am J Hematol"},{"issue":"1","key":"2019120610113563000_B40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2008.03.005","article-title":"Acquired factor XI inhibitor in systemic lupus erythematosus--case report and literature review","volume":"39","author":"Bortoli","year":"2009","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2019120610113563000_B41","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/hae.12677","article-title":"Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies","volume":"21","author":"Ichinose","year":"2015","journal-title":"Haemophilia"},{"issue":"6","key":"2019120610113563000_B42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.transci.2018.10.013","article-title":"Acquired factor XIII deficiency: a review","volume":"57","author":"Yan","year":"2018","journal-title":"Transfus Apheresis Sci"},{"issue":"6","key":"2019120610113563000_B43","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood.V65.6.1538.bloodjournal6561538","article-title":"Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management","volume":"65","author":"Bajaj","year":"1985","journal-title":"Blood"},{"issue":"7","key":"2019120610113563000_B44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203314558859","article-title":"Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature","volume":"24","author":"Mulliez","year":"2015","journal-title":"Lupus"},{"issue":"2","key":"2019120610113563000_B45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0002-9343(90)90472-P","article-title":"Circulating heparin-like anticoagulants: report of five consecutive cases and a review","volume":"88","author":"Tefferi","year":"1990","journal-title":"Am J Med"},{"issue":"5","key":"2019120610113563000_B46","first-page":"672","article-title":"Acquired heparinlike anticoagulant in a patient with metastatic breast carcinoma","volume":"143","author":"Rodgers","year":"1985","journal-title":"West J Med"},{"issue":"2","key":"2019120610113563000_B47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0038-1651106","article-title":"Heparin-like anticoagulant associated with AIDS","volume":"57","author":"de Prost","year":"1987","journal-title":"Thromb Haemost"},{"issue":"9","key":"2019120610113563000_B48","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/j.amjmed.2017.03.016","article-title":"Unexpected cause of bleeding","volume":"130","author":"Dufrost","year":"2017","journal-title":"Am J Med"},{"issue":"1","key":"2019120610113563000_B49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13052-018-0474-0","article-title":"Vitamin K deficiency: a case report and review of current guidelines","volume":"44","author":"Marchili","year":"2018","journal-title":"Ital J Pediatr"},{"issue":"1","key":"2019120610113563000_B50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1213\/ANE.0000000000002394","article-title":"The coagulation profile of end-stage liver disease and considerations for intraoperative management","volume":"126","author":"Forkin","year":"2018","journal-title":"Anesth Analg"},{"issue":"4","key":"2019120610113563000_B51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/PAT.0b013e328353254d","article-title":"Laboratory identification of factor inhibitors: an update","volume":"44","author":"Kershaw","year":"2012","journal-title":"Pathology"},{"issue":"6","key":"2019120610113563000_B52","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/bjh.12463","article-title":"Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO","volume":"162","author":"Collins","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120610113563000_B53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019120610113563000_B54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"2019120610113563000_B55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13040","article-title":"Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients","volume":"23","author":"Tarantino","year":"2017","journal-title":"Haemophilia"},{"issue":"102","key":"2019120610113563000_B56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2516.2008.01922.x","article-title":"The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients","volume":"16","author":"Zeitler","year":"2010","journal-title":"Haemophilia"},{"issue":"9","key":"2019120610113563000_B57","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2019120610113563000_B58","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2019120610113563000_B59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019120610113563000_B60","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019120610113563000_B61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019120610113563000_B62","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2017-09-800326","article-title":"Targeting anticoagulant protein S to improve hemostasis in hemophilia","volume":"131","author":"Prince","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019120610113563000_B63","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/hae.13382","article-title":"Acquired Von Willebrand syndrome and response to desmopressin","volume":"24","author":"Biguzzi","year":"2018","journal-title":"Haemophilia"},{"issue":"1","key":"2019120610113563000_B64","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/hae.13374","article-title":"A role for intravenous immunoglobulin in the treatment of acquired Von Willebrand syndrome associated with IgM gammopathy","volume":"24","author":"Lavin","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"2019120610113563000_B65","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1111\/hae.12196","article-title":"Tamoxifen for recurrent bleeds due to angiodysplasia in von Willebrand\u2019s disease","volume":"19","author":"Thachil","year":"2013","journal-title":"Haemophilia"},{"issue":"3","key":"2019120610113563000_B66","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1046\/j.1365-2141.2000.01897.x","article-title":"Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand\u2019s disease","volume":"108","author":"Bowers","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"2019120610113563000_B67","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2141.2008.07005.x","article-title":"Von Willebrand disease and angiodysplasia responding to atorvastatin","volume":"142","author":"Sohal","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120610113563000_B68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2009.08031.x","article-title":"Von Willebrand disease, angiodysplasia and atorvastatin","volume":"149","author":"Alikhan","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120610113563000_B69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/ejh.12548","article-title":"Importance of pharmacokinetic studies in the management of acquired factor X deficiency","volume":"96","author":"Lim","year":"2016","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019120610113563000_B70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.21603","article-title":"Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients","volume":"85","author":"Thompson","year":"2010","journal-title":"Am J Hematol"},{"issue":"1","key":"2019120610113563000_B71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11239-012-0818-3","article-title":"Acquired FXIII inhibitors: a systematic review","volume":"36","author":"Franchini","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2019120610113563000_B72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019120610113563000_B73","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019120610113563000_B74","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/jth.13317","article-title":"Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy","volume":"14","author":"Lavin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019120610113563000_B75","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/hae.13419","article-title":"Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease","volume":"24","author":"Khatri","year":"2018","journal-title":"Haemophilia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/80\/1546061\/hem2019000066c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/80\/1546061\/hem2019000066c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T07:08:22Z","timestamp":1722150502000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/80\/422575\/Management-of-rare-acquired-bleeding-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000066","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}